

Ilkka Liikanen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2715232/publications.pdf>

Version: 2024-02-01

23
papers

875
citations

567281

15
h-index

677142

22
g-index

23
all docs

23
docs citations

23
times ranked

1163
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus. <i>Clinical Cancer Research</i> , 2013, 19, 2734-2744. | 7.0 | 150 |
| 2 | Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients. <i>Molecular Therapy</i> , 2013, 21, 1212-1223. | 8.2 | 146 |
| 3 | Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2021, 131, . | 8.2 | 66 |
| 4 | Immunological data from cancer patients treated with Ad5/3-E2F- β 24-GMCSF suggests utility for tumor immunotherapy. <i>Oncotarget</i> , 2015, 6, 4467-4481. | 1.8 | 63 |
| 5 | Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. <i>Oncolimmunology</i> , 2015, 4, e989771. | 4.6 | 47 |
| 6 | Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2011, 19, 1858-1866. | 8.2 | 42 |
| 7 | Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: $\langle scp \rangle R \langle /scp \rangle$ results $\langle i \rangle$ in vitro $\langle /i \rangle$, in rodents and in humans. <i>International Journal of Cancer</i> , 2015, 137, 1775-1783. | 5.1 | 41 |
| 8 | Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1. <i>Clinical Cancer Research</i> , 2010, 16, 2540-2549. | 7.0 | 37 |
| 9 | Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. <i>International Journal of Cancer</i> , 2014, 135, 720-730. | 5.1 | 36 |
| 10 | Verapamil Results in Increased Blood Levels of Oncolytic Adenovirus in Treatment of Patients With Advanced Cancer. <i>Molecular Therapy</i> , 2012, 20, 221-229. | 8.2 | 33 |
| 11 | Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2259-2269. | 4.1 | 31 |
| 12 | Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. <i>Oncolimmunology</i> , 2016, 5, e1078057. | 4.6 | 29 |
| 13 | Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. <i>Molecular Therapy</i> , 2016, 24, 1323-1332. | 8.2 | 28 |
| 14 | Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2016, 24, 175-183. | 8.2 | 26 |
| 15 | Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. <i>European Journal of Cancer</i> , 2010, 46, 625-635. | 2.8 | 25 |
| 16 | Case-Control Estimation of the Impact of Oncolytic Adenovirus on the Survival of Patients With Refractory Solid Tumors. <i>Molecular Therapy</i> , 2015, 23, 321-329. | 8.2 | 14 |
| 17 | Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. <i>Journal of Translational Medicine</i> , 2013, 11, 193. | 4.4 | 13 |
| 18 | T-cell Subsets in Peripheral Blood and Tumors of Patients Treated With Oncolytic Adenoviruses. <i>Molecular Therapy</i> , 2015, 23, 964-973. | 8.2 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients. <i>Oncotarget</i> , 2018, 9, 6320-6335. | 1.8 | 10 |
| 20 | Oncolytic adenovirus decreases the proportion of TIM-3 ⁺ subset of tumor-infiltrating CD8 ⁺ T cells with correlation to improved survival in patients with cancer. , 2022, 10, e003490. | | 10 |
| 21 | Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2018, 9, 41-50. | 4.4 | 8 |
| 22 | Fate of fenestration in children treated with fontan operation. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, E233-9. | 1.7 | 6 |
| 23 | Adenoviral E4orf3 and E4orf6 Proteins, But Not E1B55K, Increase Killing of Cancer Cells by Radiotherapy in vivo. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1201-1209. | 0.8 | 3 |